Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells

• Published in: Cancer biology & therapy Vol. 16; no. 12; pp. 1794 - 1801
• Main Authors: Xu, Liang, Lei, Jingyu, Jiang, Donghai, Zhou, Lin, Wang, Shu, Fan, Weimin
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 02.12.2015
• Subjects: Antineoplastic Agents, Phytogenic - pharmacology; Apoptosis - drug effects; ATP-Binding Cassette, Sub-Family B, Member 1 - genetics; Bone Density Conservation Agents - pharmacology; breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Cell Cycle Checkpoints - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Cyclin B1 - metabolism; Drug Resistance, Neoplasm - genetics; Female; Humans; Mitosis - drug effects; multidrug resistance; paclitaxel; Paclitaxel - pharmacology; Phosphorylation; Proto-Oncogene Proteins c-bcl-2 - metabolism; raloxifene; Raloxifene Hydrochloride - pharmacology; Research Paper; multidrug resistance; paclitaxel; breast cancer; raloxifene

Raloxifene hydrochloride (RAL), one of second generation of selective estrogen receptor modulators (SERMs), is usually used in preventing osteoporosis and breast cancer. The present study evaluated whether Raloxifene might sensitize multidrug resistant (MDR) breast cancers to chemotherapies, especia...